DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Inamrinone (Inamrinone) - Summary




Inamrinone Injection USP represents a new class of cardiac inotropic agents distinct from digitalis glycosides or catecholamines.

Inamrinone (inamrinone) is indicated for the following:

Inamrinone injection is for the short-term management of congestive heart failure. Because of limited experience and potential for serious adverse effects (see ADVERSE REACTIONS), inamrinone should be used only in patients who can be closely monitored and who have not responded adequately to digitalis, diuretics, and/or vasodilators. Experience with intravenous inamrinone in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions.

Whether given orally, continuously intravenously, or intermittently intravenously, neither inamrinone nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents (including inamrinone), symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.

See all Inamrinone indications & dosage >>


Media Articles Related to Inamrinone

Congestive Heart Failure (CHF) Symptoms, Stages, and Prognosis
Source: MedicineNet Amyloidosis Specialty [2017.08.11]
Title: Congestive Heart Failure (CHF) Symptoms, Stages, and Prognosis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/11/2017 12:00:00 AM

more news >>

Page last updated: 2017-08-11

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017